Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Short Interest Update

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) saw a significant decrease in short interest in the month of May. As of May 15th, there was short interest totaling 387 shares, a decrease of 91.3% from the April 30th total of 4,431 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average daily trading volume, of 30,829 shares, the short-interest ratio is currently 0.0 days.

Institutional Trading of Matinas Biopharma

A hedge fund recently bought a new stake in Matinas Biopharma stock. DRW Securities LLC purchased a new position in shares of Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned approximately 0.72% of Matinas Biopharma at the end of the most recent quarter. 11.77% of the stock is owned by institutional investors and hedge funds.

Matinas Biopharma Stock Performance

Matinas Biopharma stock traded up $0.02 during mid-day trading on Friday, reaching $0.81. 40,360 shares of the company were exchanged, compared to its average volume of 365,239. The business has a fifty day moving average of $0.60 and a 200 day moving average of $0.67. The firm has a market cap of $5.19 million, a P/E ratio of -0.41 and a beta of 1.61. Matinas Biopharma has a 12-month low of $0.48 and a 12-month high of $3.09.

Matinas Biopharma (NYSEAMERICAN:MTNB) last posted its earnings results on Friday, May 8th. The company reported ($0.30) earnings per share for the quarter.

About Matinas Biopharma

Matinas Biopharma Inc is a clinical?stage biopharmaceutical company that specializes in the development of novel lipid?based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water?soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life?threatening fungal infections.